In this episode, host Shikha Jain, MD, speaks with Barnaby Balmforth, PhD, about the evolution of genomics in cancer care, the impact of personalized care tools and more.

•    Welcome to another exciting episode of Oncology Overdrive :58
•    About Balmforth 1:12
•    The interview 3:01
•    How did you get to where you are today? What drove you to become a leader in this space? 3:45
•    What is genomics, and why is genomic analysis important in cancer care? 7:18
•    Jain and Balmforth on the evolution of technology and challenges facing genomics and diagnostic testing to achieve personalized care for individual patients. 11:59
•    In addition to time, can you speak on the challenge of access for this type of technology? 13:20
•    How have you been able to implement “next day” test results and reports of your technology? 17:50
•    Jain and Balmforth on how Biofidelity’s technology can transform the delivery of care, as well as its psychological and mental impact. 19:06
•    What’s coming down the line for you and Biofidelity? 20:56
•    What are your thoughts for when you expand beyond thoracic oncology? What are your long-term visions for other disease sites? 24:19
•    Do you have any thoughts on AI and how it may influence genomics in cancer care? 25:51
•    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 28:37
•    How to contact Balmforth 30:37
•    Thanks for listening 31:10

Barnaby Balmforth, PhD, is co-founder and CEO of Biofidelity. Barnaby has more than 15 years’ experience in the leadership of multidisciplinary technology development.

We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Balmforth can be reached via the Biofidelity website.

Disclosures: Jain reports no relevant financial disclosures. Balmforth reports he is an employee of Biofidelity and owns shares in the company.